赤天化(600227) - 2019 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders was CNY -32,024,364.62, representing a decrease of 172.51% year-on-year [5]. - Operating revenue for the period was CNY 423,395,865.84, down 18.32% from CNY 518,338,863.02 in the same period last year [5]. - Basic earnings per share were CNY -0.0189, a decline of 174.41% from CNY 0.0254 in the same period last year [5]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -34,124,094.65, a decrease of 178.32% year-on-year [5]. - Operating profit decreased by 153.72% year-on-year, resulting in a loss of RMB 28,703,888.79, impacted by low methanol prices and reduced pharmaceutical sales [14]. - The net profit for Q1 2019 was a loss of CNY 32,407,099.13, compared to a profit of CNY 44,163,453.71 in Q1 2018, indicating a significant decline [24]. - The total profit for Q1 2019 was a loss of CNY 28,280,037.45, compared to a profit of CNY 54,083,646.81 in Q1 2018 [24]. - The total comprehensive income for Q1 2019 was a loss of CNY 32,407,099.13, compared to a profit of CNY 44,163,453.71 in Q1 2018 [25]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 6,656,570,830.28, a decrease of 0.19% compared to the end of the previous year [5]. - Total liabilities as of March 31, 2019, were CNY 549,601,001.76, an increase from CNY 534,344,643.76 at the end of 2018 [22]. - The equity attributable to shareholders was CNY 5,749,218,511.39 as of March 31, 2019, down from CNY 5,756,381,111.55 at the end of 2018 [23]. - Current liabilities included short-term borrowings of RMB 232,450,000.00, down from RMB 252,450,000.00 [19]. Cash Flow - The net cash flow from operating activities increased by 36.32% to CNY 32,689,673.59 compared to CNY 23,980,149.60 in the previous year [5]. - The cash flow from operating activities for Q1 2019 was CNY 394,347,808.99, an increase from CNY 363,889,817.09 in Q1 2018 [28]. - The company reported a total cash outflow from operating activities of ¥368,529,693.57, compared to ¥351,788,218.04 in the previous year [29]. - The net cash flow from financing activities was -¥126,747,856.01, compared to -¥109,118,138.86 in Q1 2018, indicating increased cash outflows [30]. - Investment activities generated a net cash flow of ¥89,596,509.89, a significant improvement from -¥85,866,098.00 in the previous year [33]. Shareholder Information - The total number of shareholders at the end of the reporting period was 80,344 [9]. - The largest shareholder, Guizhou Yuyang Trading Co., Ltd., held 447,733,356 shares, accounting for 26.44% of total shares [9]. Research and Development - Research and development expenses increased by 43.85% year-on-year to RMB 6,804,360.69 due to higher investment in subsidiary R&D [14]. - Research and development expenses increased to CNY 6,804,360.69 in Q1 2019, up from CNY 4,730,237.45 in Q1 2018, reflecting a growth of 43.8% [23]. Government Support - The company received government subsidies amounting to CNY 1,183,716.84 during the reporting period [5]. Market Outlook - Future outlook includes a focus on expanding R&D efforts and exploring new market opportunities [23].